There are currently 97 clinical trials in Ocala, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Renstar Medical Research, Ocala Oncology Center, Pfizer Investigational Site and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Ocala Oncology Center PL - 1102, Ocala, Florida
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
NCT05758896
Recruiting
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: Sarkis Clinical Trials, Ocala, Florida
Conditions: Contrast Induced Acute Kidney Injury
Register for Updates
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526
Recruiting
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Ocala Oncology Florida Cancer Affiliates, Ocala, Florida
Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Register for Updates
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT05011305
Recruiting
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US081, Ocala, Florida
Conditions: Nonalcoholic Steatohepatitis, Fibrosis
Register for Updates
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
NCT05365490
Recruiting
The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
11/15/2023
Locations: AdventHealth Ocala, Ocala, Florida
Conditions: Carotid Artery Diseases
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/23/2023
Locations: Ocala GI Research, Ocala, Florida
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Ocala, Florida
Conditions: Parkinson Disease
Register for Updates
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Florida Cancer Affiliates, Ocala, Florida
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307
Recruiting
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/28/2022
Locations: Renstar Medical Research, Ocala, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Breast Cancer Liquid Biopsy Trial
NCT04962529
Recruiting
The purpose of this study is to continue to develop a liquid biopsy (minimally invasive blood test) that can be used to confirm if breast cancer has spread throughout the body and if this liquid biopsy test can provide comparable information to a highly invasive tissue biopsy. The knowledge gained in this study could be used in future studies to confirm cancer recurrence using a safe and minimally invasive procedure. The research will consist of looking for tumor cell(s) circulating in the blood... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2022
Locations: Ocala Oncology, Ocala, Florida
Conditions: Breast Cancer, Cancer
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Renstar Medical Research -21 NE 1st Ave, Ocala, Florida
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Rib Fixation for Clinically Severe Rib Fractures From Trauma
NCT02595593
Recruiting
This is a multicenter randomized study investigating the differences in clinical outcomes of patients between two standard of care pathways for rib trauma: patients who receive rib fixation versus patients who receive modern critical care and pain control after sustaining clinically significant rib fractures from trauma.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/07/2022
Locations: Ocala Regional Medical Center - Health Trauma, Ocala, Florida
Conditions: Rib Fracture, Flail Chest
Register for Updates